Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Long-Term Investments (2016 - 2023)

Myriad Genetics (MYGN) has disclosed Long-Term Investments for 14 consecutive years, with $6.2 million as the latest value for Q2 2023.

  • Quarterly Long-Term Investments fell 92.1% to $6.2 million in Q2 2023 from the year-ago period, while the trailing twelve-month figure was $6.2 million through Jun 2023, down 92.1% year-over-year, with the annual reading at $54.8 million for FY2022, 7.12% down from the prior year.
  • Long-Term Investments for Q2 2023 was $6.2 million at Myriad Genetics, down from $30.4 million in the prior quarter.
  • The five-year high for Long-Term Investments was $78.5 million in Q2 2022, with the low at $6.2 million in Q2 2023.
  • Average Long-Term Investments over 5 years is $42.8 million, with a median of $45.2 million recorded in 2020.
  • The sharpest move saw Long-Term Investments skyrocketed 494.96% in 2022, then crashed 92.1% in 2023.
  • Over 5 years, Long-Term Investments stood at $47.6 million in 2019, then crashed by 55.88% to $21.0 million in 2020, then soared by 180.95% to $59.0 million in 2021, then fell by 7.12% to $54.8 million in 2022, then tumbled by 88.69% to $6.2 million in 2023.
  • According to Business Quant data, Long-Term Investments over the past three periods came in at $6.2 million, $30.4 million, and $54.8 million for Q2 2023, Q1 2023, and Q4 2022 respectively.